Evidence map›Paper›PMID 22034641›Full record

ArticleJournal of the American Society of Nephrology : JASN2011

Mutations in multiple PKD genes may explain early and severe polycystic kidney disease.

Carsten Bergmann, Jennifer von Bothmer, Nadina Ortiz Brüchle, Andreas Venghaus, Valeska Frank, Henry Fehrenbach, Tobias Hampel, Lars Pape, Annegret Buske, Jon Jonsson and 10 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 2 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 2 syntheses or guidelines pooled it, 232 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Molecular impact of a novelFrontiers in endocrinology · 2026
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. How Does ADPKD Severity Differ Between Family Members?Kidney international reports · 2024
    Review
  20. Article

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 4 countries.

Carsten BergmannCenter for Human Genetics, Bioscientia, Konrad-Adenauer-Str. 17, 55218 Ingelheim, Germany. carsten.bergmann@bioscientia.de
Jennifer von Bothmer
Nadina Ortiz Brüchle
Andreas Venghaus
Valeska Frank
Henry Fehrenbach
Tobias Hampel
Lars Pape
Annegret Buske
Jon Jonsson
Nanette Sarioglu
Antónia Santos
Jose Carlos Ferreira
Jan U Becker
Reinhold Cremer
Julia Hoefele
Marcus R Benz
Lutz T Weber
Reinhard Buettner
Klaus Zerres
RWTH Aachen University · DELudwig-Maximilians-Universität München · DEHospital Garcia de Orta · PTKernkraftwerk Gundremmingen · DEMedizinische Hochschule Hannover · DEBioScientia (Poland) · PLCharité - Universitätsmedizin Berlin · DENational University Hospital of Iceland · ISUniversity Hospital Cologne · DEUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is typically a late-onset disease caused by mutations in PKD1 or PKD2, but about 2% of patients with ADPKD show an early and severe phenotype that can be clinically indistinguishable from autosomal recessive polycystic kidney disease (ARPKD). The high recurrence risk in pedigrees with early and severe PKD strongly suggests a common familial modifying background, but the mechanisms underlying the extensive phenotypic variability observed among affected family members remain unknown. Here, we describe severely affected patients with PKD who carry, in addition to their expected familial germ-line defect, additional mutations in PKD genes, including HNF-1β, which likely aggravate the phenotype. Our findings are consistent with a common pathogenesis and dosage theory for PKD and may propose a general concept for the modification of disease expression in other so-called monogenic disorders.

Indexed as

Severity of Illness IndexAdultAgedAge of OnsetAmino Acid SequenceAryl Hydrocarbon Receptor Nuclear TranslocatorFamily HealthFemaleGenotypeHumansMaleMolecular Sequence DataPedigreePhenotypePolycystic Kidney, Autosomal DominantPregnancyARNT protein, humanAryl Hydrocarbon Receptor Nuclear TranslocatorTRPP Cation Channels

Identifiers

PMID22034641
PMCPMC3279997
OpenAlexW2124874309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.